NVO - Novo Nordisk A/S
47.16 0.00 (0.00%)
After hours: 4:02PM EDT
| Previous Close | 46.88 |
| Open | 47.16 |
| Bid | 46.50 x 100 |
| Ask | 49.45 x 200 |
| Day's Range | 46.92 - 47.38 |
| 52 Week Range | 38.05 - 58.37 |
| Volume | 1,096,590 |
| Avg. Volume | 1,627,448 |
| Market Cap | 113.923B |
| Beta | 0.82 |
| PE Ratio (TTM) | 18.58 |
| EPS (TTM) | 2.54 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.28 (2.61%) |
| Ex-Dividend Date | 2018-03-23 |
| 1y Target Est | 60.40 |
Market Realist•7 hours agoNovo Nordisk’s Saxendra Could Witness Solid Growth in 2018
In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.
- Market Realist•9 hours ago
Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth
In 4Q17, Novo Nordisk’s (NVO) hemophilia drugs NovoSeven and NovoEight generated revenues of 2.4 billion Danish kroner and 274 billion Danish kroner, respectively. That’s a ~3% and 1% YoY (year-over-year) growth in local currency.
- GlobeNewswire•9 hours ago
Emisphere Amends License Agreement with Novo Nordisk
ROSELAND, N.J., April 26, 2018-- Emisphere Technologies, Inc. today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S for the development and commercialization ...
- Market Realist•10 hours ago
Novo Nordisk’s Victoza Could See High Growth in 2018
In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.
- Market Realist•yesterday
Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.
Market Realist•yesterdayA Review of Novo Nordisk’s Modern Insulin
Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.
Market Realist•yesterdayNovo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.
- Market Realist•2 days ago
Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.
Market Realist•2 days agoOzempic Could Be Potential Driver for Novo Nordisk in 2018
In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.
- Market Realist•3 days ago
Analysts’ Recommendations for Eli Lilly & Co. on April 20
Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.
CNW Group•8 days agoXultophy® approved in Canada for the treatment of adults with type 2 diabetes
Xultophy® approved in Canada for the treatment of adults with type 2 diabetes
- Market Realist•8 days ago
Analysts’ Recommendations for Novartis on April 17
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
- Market Realist•8 days ago
Novartis’s 1Q18 Estimates: Expectations for Alcon
Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.
- Market Realist•9 days ago
Novartis’s Innovative Medicines Segment in 1Q18
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.
CNW Group•15 days agoNovo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec
Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec
CNW Group•15 days agoNovo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
- Market Realist•16 days ago
Novo Nordisk Stock Performance in 1Q18
Novo Nordisk (NVO) is a global pharmaceutical company dealing with discovery, development, manufacturing, and commercialization of pharmaceutical products. The company has segregated its business into two segments: Diabetes & Obesity Care and Biopharmaceuticals.
- Zacks•20 days ago
Novo Nordisk Obtains Licence for Sickle Cell Disease Program
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
- Reuters•21 days ago
Novo Nordisk buys blood drug licence to boost anaemic biopharma business
Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business. Novo, best known for its diabetes drugs, is on the hunt for promising assets to boost its struggling blood products business after it lost out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January. "This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business," said chief scientific officer Mads Krogsgaard Thomsen.
- GlobeNewswire•23 days ago
Status regarding Novo Nordisk's holding of its own shares (31 March 2018)
Bagsværd, Denmark, 3 April 2018 - In continuation of the company`s announcements dated 1 November 2017 and 5 February 2018 concerning planned share repurchase programmes, and pursuant to Section 204.25 ...
- GlobeNewswire•29 days ago
Market Trends Toward New Normal in Novo Nordisk A/S, Brookfield Asset Management, Dun & Bradstreet, Goldcorp, NorthStar Asset Management Group, and IMAX — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Investor's Business Daily•last month
These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status
A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.
- Insider Monkey•last month
30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets
The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]
- Reuters•last month
Drugmaker Novo Nordisk looks to former oil boss to energise M&A
Leading diabetes drugmaker Novo Nordisk (NOVOb.CO) has named former oil boss Helge Lund as its new chairman as the company contends with increasing price pressure and seeks acquisitions to broaden its blood products line-up. The man dubbed by some as Norway's Mr Oil because of his extensive career in the oil and gas industry may be more of an expert in hydrocarbons than insulin, but his merger and acquisitions experience is a big draw for the Danish pharmaceuticals company.
- Zacks•last month
Novo Nordisk Poised on Strong Pipeline Amid Competition
Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.
